Welcome to the e-CCO Library!

DOP04: Inflammatory Bowel Disease (IBD) and Solid Organ Transplantation. Natural history of pre-existing and de novo IBD patients. (EITOS study of GETECCU)
Year: 2022
Source: ECCO'22
Authors: Bastón Rey, I.(1);Calvino Suárez, C.(1);Luque, A.M.(2);Caballol, B.(3);Soutullo, C.(4);Bravo, A.(5);Castaño, A.(6);Gros, B.(7);Bernal, L.(8);Diz Lois, M.T.(9);Alonso Galán, H.(10);Cañete, F.(11);Castro, B.(12);Pérez Galindo, P.(13);González Muñoza, C.(14);El Hajra, I.(15);Martínez Montiel , P.(16);Alonso Abreu, I.(17);Mesonero, F.(18);González Vivo, M.(19);Peries, L.(20);Martín Arranz, E.(21);Abril, C.(22);Marín Jiménez, I.(23);Baltar, R.(24);Vicuna, M.(25);Moreno, N.(26);Brunet, E.(27);Rubín de Célix, C.(28);Fajardo, I.(29);Cruz, N.(30);Rojas Feria, M.(2);Fernández Clotet, A.(3);Gimeno, M.(4);Zabana, Y.(31);Suárez Ferrer, C.(21);Rodríguez Lago, I.(32);Barreiro de Acosta, M.(1);
Created: Friday, 11 February 2022, 3:52 PM
DOP04: Matching between donors and patients in fecal microbiota transplantation is important for long-term maintenance on Ulcerative Colitis
Year: 2020
Source: ECCO'20 Vienna
Authors: Dai Ishikawa
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP04: Screening and management of fistula cancers in patients with perianal fistulising Crohn’s Disease: an expert consensus
Year: 2024
Source: ECCO'24 Stockholm
Authors: Wong, Serre-Yu
Created: Tuesday, 30 April 2024, 5:03 PM
DOP04: Single cell RNA sequencing identifies distinct intestinal inflammation patterns between primary sclerosing cholangitis-associated colitis and Ulcerative Colitis
Year: 2021
Source: ECCO'21 Virtual
Authors: Uniken Venema, W.(1);Bangma, A.(1);Van der Wijst, M.(2);Kats-Ugurlu, G.(1);Bjork, J.(1);Vich Vila, A.(1);Weersma, R.(1);Festen, E.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP04: Single cell RNA sequencing reveals a potential role for IFNγ in priming circulating monocytes for intestinal inflammatory function in Crohn's Disease.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Hornsby, E.(1)*;Gadhok, R.(1);Yadon, A.N.(2);Lindsay, J.O.(1);Stagg, A.J.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP04: The ability of epithelial regeneration is reduced in the Crohn’s disease patient-derived organoids, especially in TNF-α enriched condition
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. H. Song1, S. N. Hong*1, G. Seong1, T. J. Kim1, E. R. Kim1, D. K. Chang1, Y-H. Kim1, C. Lee1, C. Lee1

Created: Friday, 22 February 2019, 9:41 AM
DOP05 Perioperative Dietary Therapy in inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Adamina1, K. Gerasimidis2, R. Sigall-Boneh3,4, O. Zmora5, A. de Buck van Overstraeten6,7, M. Campmans-Kuijpers8, P. Ellul9, K. Katsanos10, P. Kotze11, N. Noor12, J. Schäfli-Thurnherr13, S. Vavricka13, C. Wall14, N. Wierdsma15, N. Yassin16, M. Lomer17, ECCO Topical Review on Perioperative Dietary Therapy in Inflammatory Bowel Disease

Created: Thursday, 30 January 2020, 10:12 AM
DOP050: Influence of disease location on vedolizumab efficacy in Inflammatory Bowel Disease: A real-life multicentre experience
Year: 2018
Source: ECCO'18 Vienna
Authors: Pestour Sandie
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP050: Influence of disease location on vedolizumab efficacy in inflammatory bowel disease: a real-life multicentre experience
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Pestour1*, S. Nancey2, A.L. Charlois2, B. Bonaz1, B. Flourie2, G. Boschetti2, N. Mathieu1

Created: Thursday, 21 February 2019, 9:14 AM
DOP050: Serum proteomic analysis defines novel circulating inflammatory markers for Crohn's disease and response to anti-TNF therapy
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Korf H.*1,2, Sabino J.1, Ballet V.3, de Bruyn M.1,4, Van Assche G.3, Ferrante M.3, Vermeire S.3

Created: Wednesday, 20 February 2019, 10:36 AM
DOP050: The efficacy of vedolizumab by disease activity and prior tumour necrosis factor-alpha antagonist failure in patients with ulcerative colitis or Crohns disease: post-hoc analyses from the GEMINI 1 and GEMINI 2 studies
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

G. D’Haens1, J.-F. Colombel*2, M. Dubinsky2, B. Abhyankar3, A. James3, K. Lasch4

Created: Friday, 22 February 2019, 9:49 AM
DOP051: Response and remission rates with up to 3 years of vedolizumab treatment in patients with ulcerative colitis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

E.V. Loftus Jr1, J.-F. Colombel*2, A. Previtali3, M. Smyth3

Created: Friday, 22 February 2019, 9:49 AM
DOP051: Serological biomarkers of tissue turnover can early identify responders to infliximab in Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

van Haaften W.T.*1,2, Mortensen J.H.3, Olesen M.L.3,4, Karsdal M.A.3, Olinga P.2, Bay-Jensen A.-C.3, Dijkstra G.1

Created: Wednesday, 20 February 2019, 10:36 AM
DOP051: Serological biomarkers of tissue turnover can early identify responders to infliximab in Crohn’s Disease
Year: 2017
Source: ECCO'17 Barcelona
Authors: van Haaften W.
Crohn's disease, Inflixmab, Fibroblast, Fibrosis, Mesenchymal cell
Files: 1
DOP051: Shorter disease duration is associated with higher response rates to vedolizumab in Crohn’s disease but not ulcerative colitis: a multi-centre consortium analysis
Year: 2018
Source: ECCO '18 Vienna
Authors:

D. Faleck1, A. Winters1, S. Chablaney1, P. Shashi2, J. Meserve3, A. Weiss4, S. Aniwan5, J.L. Koliani-Pace6, G. Kochhar2, B. Boland3, S. Singh3, R. Hirten1, E. Shmidt1, K. Lasch7, M. Luo7, M. Bohm8, S. V Sagi8, M. Fischer8, D. Hudesman9, S. Chang9, D. Lukin4, K. Sultan10, A. Swaminath11, N. Gupta12, C.A. Siegel6, B. Shen2, W.J. Sandborn3, S. Kane5, E.V. Loftus5, B.E. Sands1, J.-F. Colombel1, P.S. Dulai3*, R. Ungaro1

Created: Thursday, 21 February 2019, 9:14 AM
DOP052: Molecular response to ustekinumab in moderate-to-severe Crohn's disease by serum protein and biopsy gene expression analysis: results from Ustekinumab phase 3 studies
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Li K., Hayden K., Wadman E., Bhagat S., Emrich S., Jacobstein D., Gasink C., Brodmerkel C.

Created: Wednesday, 20 February 2019, 10:36 AM